MX2007004833A - 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolin ocarbonitrilos para el tratamiento de lesion isquemica. - Google Patents
4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolin ocarbonitrilos para el tratamiento de lesion isquemica.Info
- Publication number
- MX2007004833A MX2007004833A MX2007004833A MX2007004833A MX2007004833A MX 2007004833 A MX2007004833 A MX 2007004833A MX 2007004833 A MX2007004833 A MX 2007004833A MX 2007004833 A MX2007004833 A MX 2007004833A MX 2007004833 A MX2007004833 A MX 2007004833A
- Authority
- MX
- Mexico
- Prior art keywords
- quinolinecarbonitriles
- ethynyl
- methoxyphenyl
- dichloro
- alkoxy
- Prior art date
Links
- -1 2,4-dichloro-5-methoxyphenyl Chemical group 0.000 title 1
- 208000037906 ischaemic injury Diseases 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62128004P | 2004-10-22 | 2004-10-22 | |
| PCT/US2005/037839 WO2006047262A1 (en) | 2004-10-22 | 2005-10-21 | 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007004833A true MX2007004833A (es) | 2007-05-16 |
Family
ID=35784691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007004833A MX2007004833A (es) | 2004-10-22 | 2005-10-21 | 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolin ocarbonitrilos para el tratamiento de lesion isquemica. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20060116375A1 (enExample) |
| EP (1) | EP1802581B1 (enExample) |
| JP (1) | JP2008517924A (enExample) |
| KR (1) | KR20070085413A (enExample) |
| CN (1) | CN101044117A (enExample) |
| AT (1) | ATE391122T1 (enExample) |
| AU (1) | AU2005299822A1 (enExample) |
| BR (1) | BRPI0516995A (enExample) |
| CA (1) | CA2581807A1 (enExample) |
| CR (1) | CR9072A (enExample) |
| DE (1) | DE602005005843T2 (enExample) |
| DK (1) | DK1802581T3 (enExample) |
| EC (1) | ECSP077385A (enExample) |
| ES (1) | ES2303287T3 (enExample) |
| IL (1) | IL182547A0 (enExample) |
| MX (1) | MX2007004833A (enExample) |
| NO (1) | NO20071708L (enExample) |
| PL (1) | PL1802581T3 (enExample) |
| PT (1) | PT1802581E (enExample) |
| RU (1) | RU2007111704A (enExample) |
| SI (1) | SI1802581T1 (enExample) |
| WO (1) | WO2006047262A1 (enExample) |
| ZA (1) | ZA200703275B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200829555A (en) * | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| CN102952037A (zh) * | 2012-11-18 | 2013-03-06 | 大连九信生物化工科技有限公司 | 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法 |
| WO2014086284A1 (zh) * | 2012-12-04 | 2014-06-12 | 上海医药集团股份有限公司 | 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途 |
| CN114436851B (zh) * | 2022-01-17 | 2023-08-22 | 常州大学 | 一种n,n-二甲基苄胺及其衍生物的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US20040229880A1 (en) * | 2003-02-21 | 2004-11-18 | Wyeth | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
-
2005
- 2005-10-21 RU RU2007111704/04A patent/RU2007111704A/ru not_active Application Discontinuation
- 2005-10-21 AT AT05820982T patent/ATE391122T1/de not_active IP Right Cessation
- 2005-10-21 KR KR1020077011472A patent/KR20070085413A/ko not_active Withdrawn
- 2005-10-21 BR BRPI0516995-0A patent/BRPI0516995A/pt not_active IP Right Cessation
- 2005-10-21 US US11/255,556 patent/US20060116375A1/en not_active Abandoned
- 2005-10-21 DE DE602005005843T patent/DE602005005843T2/de not_active Expired - Lifetime
- 2005-10-21 SI SI200530255T patent/SI1802581T1/sl unknown
- 2005-10-21 PL PL05820982T patent/PL1802581T3/pl unknown
- 2005-10-21 MX MX2007004833A patent/MX2007004833A/es active IP Right Grant
- 2005-10-21 JP JP2007538054A patent/JP2008517924A/ja not_active Withdrawn
- 2005-10-21 PT PT05820982T patent/PT1802581E/pt unknown
- 2005-10-21 CA CA002581807A patent/CA2581807A1/en not_active Abandoned
- 2005-10-21 WO PCT/US2005/037839 patent/WO2006047262A1/en not_active Ceased
- 2005-10-21 EP EP05820982A patent/EP1802581B1/en not_active Expired - Lifetime
- 2005-10-21 AU AU2005299822A patent/AU2005299822A1/en not_active Abandoned
- 2005-10-21 CN CNA2005800360383A patent/CN101044117A/zh active Pending
- 2005-10-21 ES ES05820982T patent/ES2303287T3/es not_active Expired - Lifetime
- 2005-10-21 DK DK05820982T patent/DK1802581T3/da active
-
2007
- 2007-03-30 NO NO20071708A patent/NO20071708L/no not_active Application Discontinuation
- 2007-04-11 EC EC2007007385A patent/ECSP077385A/es unknown
- 2007-04-12 IL IL182547A patent/IL182547A0/en unknown
- 2007-04-20 CR CR9072A patent/CR9072A/es not_active Application Discontinuation
- 2007-04-20 ZA ZA200703275A patent/ZA200703275B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1802581T1 (sl) | 2008-08-31 |
| BRPI0516995A (pt) | 2008-09-30 |
| NO20071708L (no) | 2007-07-13 |
| RU2007111704A (ru) | 2008-11-27 |
| KR20070085413A (ko) | 2007-08-27 |
| EP1802581B1 (en) | 2008-04-02 |
| PT1802581E (pt) | 2008-06-03 |
| DK1802581T3 (da) | 2008-06-30 |
| DE602005005843D1 (de) | 2008-05-15 |
| DE602005005843T2 (de) | 2009-05-14 |
| AU2005299822A1 (en) | 2006-05-04 |
| WO2006047262A1 (en) | 2006-05-04 |
| CR9072A (es) | 2007-09-07 |
| PL1802581T3 (pl) | 2008-09-30 |
| CA2581807A1 (en) | 2006-05-04 |
| ECSP077385A (es) | 2007-05-30 |
| CN101044117A (zh) | 2007-09-26 |
| IL182547A0 (en) | 2007-09-20 |
| US20060116375A1 (en) | 2006-06-01 |
| ES2303287T3 (es) | 2008-08-01 |
| EP1802581A1 (en) | 2007-07-04 |
| JP2008517924A (ja) | 2008-05-29 |
| HK1104555A1 (en) | 2008-01-18 |
| ATE391122T1 (de) | 2008-04-15 |
| ZA200703275B (en) | 2008-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502912A5 (enExample) | ||
| EA201000050A1 (ru) | Замещенные бициклолактамные соединения | |
| AP1541A (en) | New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors. | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| BRPI0418181A (pt) | emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson | |
| MXPA05008706A (es) | 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas. | |
| RU2011112684A (ru) | АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| MY139704A (en) | Naphthalene derivatives for use as histamine-3-receptor ligands | |
| TW200727893A (en) | Methods for treating sexual dysfunction | |
| MY158069A (en) | Tricyclic compound and pharmaceutical use thereof | |
| CA2592345A1 (en) | Piperidine and azetidine derivatives as glyt1 inhibitors | |
| ZA200703275B (en) | 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinollnecarbonitriles for the treatment of ischemic Injury | |
| WO2009008345A1 (ja) | 金属錯体化合物、これを有効成分とする癌治療剤組成物および該金属錯体化合物用の中間体 | |
| TW200724539A (en) | Benzimidazole derivative and use thereof | |
| CY1110950T1 (el) | Ενωσεις ιμιδαζολιδινονυλ αμινοπυριμιδινης για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| NO20080481L (no) | Kinolinderivater som antibakterielle midler | |
| JP2005502656A5 (enExample) | ||
| MX2009006634A (es) | Compuestos de imidazolidinonil aminopirimidina para el tratamiento de cancer. | |
| TW200635898A (en) | Benzoyl-tetrahydropyridine | |
| MX2009007850A (es) | Tratamiento de incontinencia fecal. | |
| TW200738637A (en) | Compounds having activity at NK3 receptor and uses thereof in medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |